Onesource Specialty Pharma Limited

Onesource Specialty Pharma Limited (ONESOURCE) is a small-cap Healthcare company valued at ₹16,154 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move

Onesource Specialty Pharma Limited last traded at ₹1,415, modestly down 1.27% on the day.

Recent developments

2026-07-14: OneSource Specialty Pharma signed a partnership with Germany’s Formycon to manufacture biosimilars, which could boost its CDMO services and expand its market reach in the biologics sector.

Financial performance

The company's business is improving, with revenue rising 37.3% in the latest quarter compared to the same quarter a year earlier. Annual revenue fell 1.6% year-over-year, but net profit swung from a loss of ₹18 crore to a loss of ₹74 crore, widening the annual net loss. The net profit margin deteriorated to -5.2% from -1.2% in the prior year, and return on equity remains negative at -1.3%.

Valuation multiples

A price-to-earnings ratio is not meaningful here because the company is loss-making; the stock trades at 3.04 times book value.

Things to watch

The company reported a net loss of ₹74 crore in its latest financial year, widening from a loss of ₹18 crore the previous year. The net profit margin has deteriorated to -5.2%, and return on equity remains negative at -1.3%. The stock is 21.7% below its 52-week high.

Where it stands

OneSource Specialty Pharma ended the latest quarter with revenue of ₹449 crore, up 37.3% from the same quarter a year earlier, while net profit reached ₹25 crore. The company's net loss widened significantly in the annual period, and the net profit margin has declined sharply. The stock is 21.7% below its 52-week high.

Summarised by DocStoX's model on 2026-10-03 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.